The biosimilars market has moved from being a niche segment of the pharmaceutical industry to a strategic pillar of global healthcare systems. As biologic drugs lose patent protection and healthcare budgets tighten, biosimilars are no longer viewed as “alternatives” but as essential tools for improving patient access and system sustainability. This article presents...